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In calves (Fig.1), magnitude and duration of fecal O157:H7 shedding was similar for the oral treatment group and the control group. Animals in both groups were 
excreting bacteria in the feces during at least 54 days. In contrast, rectal administration of LF induced a reduction in fecal E. coli O157:H7 excretion from day 8 
onwards. The shedding pattern of the rectal treatment group and the control group was significantly different from days 19 to 22 and days 33 to 36 (p ≤ 0.05). On 
day 12, two animals from the rectal treatment group already ceased excreting E. coli O157:H7. Both stayed negative till the end of the experiment (day 36) without 
further LF administration, even though the other animal in this group remained positive by direct enumeration until day 26. In sheep (Fig.2), the oral administration 
of 0,3 g LF/day could not reduce the excretion of E. coli. Therefore, after 19 days of treatment, we raised the daily dose to 3 g LF/day.  Subsequently, fecal shedding 
decreased in the LF group, although there was no significant difference between the LF group and the control group. 
 
 
 
Food contamination with E. coli O157:H7 by ruminant manure has been 
reported as the primary source of human infection, therefore inhibition of       
E. coli O157:H7 colonization and shedding in ruminants could control the risk 
of human exposure to this pathogen. To evaluate a new treatment approach, 
we studied the ability of bovine lactoferrin (Lf), a natural antimicrobial protein 
of milk, to reduce E. coli O157:H7 infections in calves and in sheep. 
In a first study, 9 calves were orally inoculated and  re-inoculated 7 days later 
with 1010 CFU E. coli O157:H7 for 2 consecutive days. On day 3 after re-infection, 
3 calves were orally administered 3 g lactoferrin per day for 51 days (oral 
treatment group) and 3 calves were rectally treated with 300 mg lactoferrin per 
day for 33 days (rectal treatment group). In a second study, 10 sheep were 
orally inoculated with 1010 CFU E. coli O157:H7 for 2 consecutive days. On day 3 
after infection, 5 sheep were orally treated with 300 mg lactoferrin a day          
(Lf group) and after 19 days with 3 g a day for 14 days. In both studies, the 
colonization control animals were sham-treated with PBS orally. Fecal excretion 
was monitored 2 times a week by direct plating and an enrichment. 
Our data demonstrate the reduction of E. coli O157:H7 shedding in calves and sheep due to administration of lactoferrin. In conclusion, lactoferrin could be used to 
clear E. coli O157:H7 infection in ruminants and could thereby reduce the zoonotic risk for humans.   
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Fig.2 Average of E. coli O157:H7 excretion following infection and oral LF treatment of sheep. 
Compared to the control group, excretion in the LF group decreases faster when administering 
3g LF/day (not statistically significant).  
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Fig.1 Average of E. coli O157:H7 excretion following infection, oral and rectal LF treatment of 
calves. x Significant differences in bacteria excretion between control and rectal treatment 
groups, + Significant differences in bacteria excretion between oral and rectal treatment  groups, 
† Euthanasia. 
